INTERNATIONAL PATENT: TAKEDA PHARMACEUTICAL COMPANY LIMITED FILES APPLICATION FOR "DOSING REGIMENS OF ANTI-CD38 ANTIBODIES FOR TREATMENT OF SUBJECTS WITH IMMUNOGLOBULIN A NEPHROPATHY"

GENEVA, Nov. 19 -- TAKEDA PHARMACEUTICAL COMPANY LIMITED (1-1, Doshomachi 4-chome, Chuo-kuOsaka-shiOsaka, 541-0045) filed a patent application (PCT/US2025/028689) for "DOSING REGIMENS OF ANTI-CD38 ANTIBODIES FOR TREATMENT OF SUBJECTS WITH IMMUNOGLOBULIN A NEPHROPATHY" on May 09, 2025. With publication no. WO/2025/235919, the details related to the patent application was published on Nov 13, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): HOMSY, Jason (c/o Takeda Development Center Americas, Inc.95 Hayden AvenueLexington, MA 02421), FEDYK, Eric (120 Bigelow DriveSudbury, MA 01776)

Abstract: ...